This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Firms Oppose Bid for Chiron

Three shareholders owning 12.3% of Chiron's (CHIR) stock say they oppose an offer by Novartis (NVS - Get Report) to buy the shares that the Swiss company doesn't already own.

The announcement heightens the uncertainty of Novartis' takeover bid, which is worth $45 a share, or $5.1 billion. Novartis now owns 44% of Chiron.

News of the holdouts sent Chiron's stock to a 52-week high of $45.32, up 61 cents, or 1.4% for the day, on nearly twice the average daily volume. After hours, the stock slipped 3 cents.

The new opponents join ValueAct Capital , a San Francisco investment management firm, in vowing to vote against the deal. ValueAct owns 5.2% of Chiron's shares.

One of the dissidents, CAM North America LLC, announced the newest opposition in a filing with the Securities and Exchange Commission. New York-based CAM and two other investment advisory firms now resisting the bid -- Smith Barney Fund Management LLC and Salomon Brothers Asset Management Inc. -- hold about 23.2 million shares.

In order to complete the deal, Novartis needs approval by a majority of Chiron shareholders, excluding the stock controlled by Novartis. ValueAct owns about 9.8 million of Emeryville, Calif.-based Chiron's shares. Together, the four opponent firms own 17.5% of all Chiron shares. More importantly, their holdings represent about 30% of the shares eligible to vote.

"We believe the merger consideration offered by Novartis of $45 in cash per Chiron share is financially inadequate," says Richard A. Freeman, managing director of CAM North America, in a Jan. 25 letter to Chiron that was enclosed in the SEC filing.

Although Novartis raised its buyout bid to $45 a share in October after Chiron's board rejected an earlier $40-a-share proposal, Novartis says it won't pay more . Novartis already has announced how the various Chiron units -- vaccines, blood testing and biopharmaceuticals -- will be absorbed.

The deal has been approved by the Federal Trade Commission. It still requires clearance from the European Union and Chiron's shareholders.

A shareholders' rebellion creates a dilemma for both companies. Chiron has already signaled it would be better off being owned by someone else rather than being independent. If the shareholders say "no" and Novartis won't budge on price, the question would be: Could Chiron attract another buyer, knowing that Novartis owns a giant piece of the company?

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NVS $75.97 -1.09%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs